

October 12, 2017



UPDATE: Heat Biologics to Present at the Upcoming BIO Investor Forum in San Francisco

DURHAM, NC / October 12, 2017 / [Heat Biologics, Inc.](http://www.heatbio.com) ("Heat") (NASDAQ: HTBX), a biopharmaceutical company developing immunotherapies designed to activate a patient's immune system against cancer, will present during the BIO Investor Forum next week in San Francisco.

Jeff Wolf, CEO of Heat, will present at 11:15 a.m. PT, on Tuesday, Oct. 17, 2017*, with the presentation broadcast live at <http://www.veracast.com/webcasts/bio/investorforum2017/83114339421.cfm> for those who cannot attend. Mr. Wolf will also be available to participate in one-on-one meetings with investors registered to attend the conference.

The BIO Investor Forum is an international biotech investor conference focused on early and established private companies, as well as emerging public companies. The event features plenary sessions, business roundtables, therapeutic workshops, company presentations, and One-on-One Partnering™ meetings.

**Updated date/time from original June 12, 2017, announcement*

About Heat Biologics, Inc.

Heat Biologics is a biopharmaceutical company developing immunotherapies designed to activate a patient's immune system against cancer using of CD8+ "Killer" T-cells. Our T-Cell Activation Platform (TCAP) produces therapies designed to turn "cold" tumors "hot" and be administered in combination with checkpoint inhibitor therapies and other immuno-modulators to increase their effectiveness. We are currently enrolling patients in our Phase 2 clinical trial for non-small cell lung cancer, in combination with Bristol-Myers Squibb's nivolumab (Opdivo®). We also have numerous pre-clinical programs at various stages of development. For more information, please visit www.heatbio.com.

Contact

For Media and Investor Inquiries
Melissa M Conger
Heat Biologics
+1 919 289 4017

mconger@heatbio.com